On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the first company to treat a genetic condition by editing RNA at the ...
The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular ...
Editing Without 'Cutting': Molecular Mechanisms ... 12, 2024 — The rise of RNA viruses like SARS-CoV-2 highlights the need for new ways to fight them. RNA-targeting tools like CRISPR/Cas13 ...
At the Breakthroughs in Muscular Dystrophy special meeting held in Chicago Nov. 19-20, 2024, and organized by the American Society of Gene & Cell Therapy (ASGCT), multiple interventions at the RNA ...